YFY Biotech Management Company

What YFY Biotech Management Company does

YFY Biotech Management Company (上騰生技顧問股份有限公司) is a Taipei-based, privately held biotechnology investment and consulting firm founded in 2003 by the YFY Group (永豐餘集團). The firm manages the Taiwan Global Biofund, established in 2005, and provides investment, incubation, and management-consulting services to Taiwanese biotechnology companies across therapeutics, drug delivery, medical devices, and biosimilars. Its named portfolio includes 中裕新藥 (4147, HIV biologics), 太景 (4157, antivirals), 台微體 (4152, liposomal delivery), 益安 (6499, medical devices), 萊鎂醫 (6633, sleep apnea devices), and 永昕 (4726, biosimilars), with portfolio companies publicly listed on the Taiwan Stock Exchange.

The firm markets a multi-disciplinary bench covering biomedical technology, intellectual property management, policy and regulation, operations management, financial financing, and capital fundraising, positioning itself as a cross-functional partner spanning industry, government, academia, and research. The team's stated value proposition is to bridge capital, regulatory, and operational gaps for Taiwan-based biotech issuers; distribution is essentially direct via the corporate website (tgbfund.com.tw) and portfolio news updates. There is no traditional technology product; the "platform" is the Taiwan Global Biofund vehicle combined with hands-on consulting engagements delivered by a sub-10-person team.

Revenue mechanics are not disclosed; the firm operates as a private subsidiary within the YFY Group conglomerate with no public shareholders, external institutional investors, or audited revenue figures in the source data. Pricing and fee structure for both fund management and consulting services are not publicly disclosed. Operating geography is concentrated in Taiwan, with portfolio expansion signals into Greater China (e.g., Pixavir China approval in December 2025) flowing indirectly through investees rather than via direct geographic build-out by the GP itself. The firm carries no certifications, patents, or disclosed compliance frameworks in the source material, and its contact footprint is a single Taipei headquarters with phone (02-2396-8020) and email ([email protected]).

Name

YFY Biotech Management Company

Legal name

YFY Biotech Management Company

Website

https://tgbfund.com.tw

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

YFY Biotech Management Company is a Taipei-based, privately held biotech investment and consulting firm founded in 2003 by the YFY Group, managing the Taiwan Global Biofund and providing capital and operational advisory to Taiwanese biotech issuers across therapeutics, devices, and biosimilars.

Ownership category

akta.pro rank

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Others

Revenue model

1. Fund Management: Manages Taiwan Global Biofund, established in 2005, providing investment and consulting services to biotech companies

Marketing channels1 record

Core offering

YFY Biotech Management Company (上騰生技顧問股份有限公司) is a biotechnology investment and consulting firm established by YFY Group in 2003 that manages the Taiwan Global Biofund (established in 2005). The firm invests in and provides operational management consulting to biotech companies, with expertise spanning biomedical technology, intellectual property management, policy and regulation, operations management, financial services, and capital fundraising.

Product overview

YFY Biotech Management Company (上騰生技顧問股份有限公司), established by the YFY Group in 2003, is a biotechnology investment and consulting company that manages the Taiwan Global Biofund (established in 2005). The company provides biotech company investment and management consulting services, with experts covering fields including biomedical technology, intellectual property management, policy regulations, operations management, financial financing, and capital fundraising. The company does not appear to offer a traditional technology product; rather, it operates as a fund management and investment consultancy firm in the biotechnology sector with portfolio companies including 太景 (4157), 中裕 (4147), 台微體 (4152), 永昕 (4726), and others.

Differentiator

Problem solved

Functional benefit

Brands

• Taiwan Global Biofund: A venture capital fund established by YFY Biotech Management Company in 2005 for biotechnology investments

Products and services

• Taiwan Global Biofund (上智生技創投)
• Biotechnology Investment and Management Consulting

Named customers6 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves3 records

Expansion highlights3 records

Direct peers

• Taiwania Capital Management: Taiwan-based venture capital firm with dedicated life sciences and biotech investment funds. Closest peer as a Taiwan-focused institutional biotech investor with similar portfolio-stage orientation.
• WI Harper Group: Cross-border early-stage VC with biotech and healthcare exposure and deep Taiwan/Asia roots. Comparable as a regional biotech investor providing both capital and operating support.
• CDIB Capital Group: Taiwanese venture and private equity firm with healthcare and life sciences exposure. Comparable as a Taiwan-based fund manager with biotech allocation and LP-backed capital base.

Broad incumbents

• OrbiMed Advisors: Global healthcare-dedicated investment firm across venture, growth, and public equities. Comparable as a healthcare-focused fund manager with significantly broader scale and global mandate.
• RA Capital Management: Healthcare-focused crossover fund investing across development stages. Comparable as a biotech-dedicated manager using deep scientific diligence and operating expertise to support portfolio companies.
• Flagship Pioneering: Biotechnology-focused platform that creates and invests in biotech companies from inception. Comparable as a biotech-specialist investor with operating expertise, but at far larger scale and global reach.
• ARCH Venture Partners: US-based venture firm focused on early-stage biotech and technology companies. Comparable as a biotech-specialist fund manager with deep scientific expertise and operating support.
• Hillhouse Capital Management: Asia-focused investment firm with a dedicated healthcare and life sciences franchise. Comparable as a larger, broader investment manager with material biotech allocation in the region.

Regional players

• Nan Fung Life Sciences: Hong Kong-based life sciences investment platform backed by the Nan Fung Group. Comparable as a Greater China regional biotech investor with conglomerate backing.
• Qiming Venture Partners: China-focused venture firm with active healthcare and biotech practice. Comparable as an Asia-focused biotech investor operating across the region with similar fund-management structure.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about YFY Biotech Management Company